{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:22:06Z","timestamp":1791199326381,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Crinetics Pharmaceuticals, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acromegaly is a rare endocrine disease caused by excessive growth hormone (GH) secretion typically due to a pituitary adenoma. Patients ineligible for or with an inadequate response to surgery and\/or radiotherapy often require pharmacotherapy such as depot somatostatin receptor ligand (SRL) injections. This study evaluated the current management of patients with acromegaly and real-world experience of disease burden, treatment burden, and healthcare resource utilization (HCRU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A quantitative study was conducted among symptomatic adults with acromegaly receiving therapy, including depot SRL injections. A web-based survey captured the 3-month disease experience including the presence and severity of acromegaly-associated symptoms, treatment experience, HCRU, and impact on the ability to work (Work Productivity and Impairment Questionnaire [WPAI], assessed over prior 7 days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 58 patients who completed the survey, 36 (62.1%) received a depot SRL injection, either as monotherapy (18 [50%]), or in combination with other agents. All patients experienced\u2009\u2265\u20091 symptom during the previous 3 months, with 67% having\u2009\u2265\u20091 symptom with a severity of \u2265\u20098 on a scale of 0 to 10. Patients reported that acromegaly had a moderate (59%) or high (22%) level of interference in their life overall. Of 18 patients on depot SRL injection monotherapy, 12 (67%) reported\u2009\u2265\u20091 breakthrough acromegaly symptom at any time prior to the next injection. WPAI scores were 51% for daily activity impairment, 38% for presenteeism, 34% for overall work impairment, and 8% for absenteeism. Patients receiving depot SRL injection (monotherapy\/combination therapy) were more likely than those not receiving this injection to report moderate-to-high interference of acromegaly treatment with their life (56%\/72% vs. 18%) and that their treatment was moderately to highly burdensome (67%\/72% vs. 41%). HCRU due to acromegaly treatment included: a mean of 2.6 office visits, 13.8% with \u2265\u20091 emergency department visit, and 10.3% with \u2265\u20091 overnight hospitalization. When asked about treatment preferences, 60% of patients preferred oral therapy and 22% injectable mediation; 81% preferred a therapy that can be taken at home.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite current pharmacotherapies, patients reported substantial burden due to acromegaly and its treatment, which extends beyond clinical manifestations to impact activities, productivity, and HCRU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-025-00965-3","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:15:50Z","timestamp":1764944150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world burden of disease, treatment, and healthcare resource utilization in acromegaly: a quantitative survey of patient experiences"],"prefix":"10.1186","volume":"9","author":[{"given":"Maxwell","family":"Koobatian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Sisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janetricks C.","family":"Okeyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany P.","family":"Quock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"1","key":"965_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM et al (2019) Acromegaly. Nat Rev Dis Primers 5(1):20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"965_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10(11):804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"965_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12020-018-1764-4","volume":"63","author":"P Caron","year":"2019","unstructured":"Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B et al (2019) Signs and symptoms of acromegaly at diagnosis: the physician\u2019s and the patient\u2019s perspectives in the ACRO-POLIS study. Endocrine 63(1):120\u2013129. https:\/\/doi.org\/10.1007\/s12020-018-1764-4","journal-title":"Endocrine"},{"issue":"4","key":"965_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11102-023-01322-7","volume":"26","author":"TNA Slagboom","year":"2023","unstructured":"Slagboom TNA, van Bunderen CC, De Vries R, Bisschop PH, Drent ML (2023) Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary 26(4):319\u2013332. https:\/\/doi.org\/10.1007\/s11102-023-01322-7","journal-title":"Pituitary"},{"issue":"1","key":"965_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268\u2013332. https:\/\/doi.org\/10.1210\/er.2018-00115","journal-title":"Endocr Rev"},{"issue":"1","key":"965_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2018) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179(1):59\u201371. https:\/\/doi.org\/10.1530\/EJE-18-0255","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"965_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/jim-2017-000570","volume":"66","author":"S Liu","year":"2018","unstructured":"Liu S, Adelman DT, Xu Y, Sisco J, Begelman SM, Webb SM et al (2018) Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med 66(3):653\u2013660. https:\/\/doi.org\/10.1136\/jim-2017-000570","journal-title":"J Investig Med"},{"issue":"12","key":"965_CR8","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.18553\/jmcp.2015.21.12.1106","volume":"21","author":"H Placzek","year":"2015","unstructured":"Placzek H, Yaping Xu Y, Mu Y, Begelman SM, Fisher M (2015) Clinical and economic burden of commercially insured patients with acromegaly in the united states: a retrospective analysis. J Manag Care Spec Pharm 21(12):1106\u20131112. https:\/\/doi.org\/10.18553\/jmcp.2015.21.12.1106","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"965_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/13696998.2021.1898968","volume":"24","author":"A Ribeiro-Oliveira Jr","year":"2021","unstructured":"Ribeiro-Oliveira A Jr., Brook RA, Munoz KA, Beren IA, Whalen JD, Kleinman NL et al (2021) Burden of acromegaly in the united states: increased health services utilization, location of care, and costs of care. J Med Econ 24(1):432\u2013439. https:\/\/doi.org\/10.1080\/13696998.2021.1898968","journal-title":"J Med Econ"},{"issue":"1","key":"965_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000375451","volume":"103","author":"SM Webb","year":"2016","unstructured":"Webb SM, Badia X (2016) Quality of life in acromegaly. Neuroendocrinology 103(1):106\u2013111. https:\/\/doi.org\/10.1159\/000375451","journal-title":"Neuroendocrinology"},{"key":"965_CR11","doi-asserted-by":"publisher","first-page":"101389","DOI":"10.1016\/j.ghir.2021.101389","volume":"59","author":"MD Whittington","year":"2021","unstructured":"Whittington MD, Munoz KA, Whalen JD, Ribeiro-Oliveira A, Campbell JD (2021) Economic and clinical burden of comorbidities among patients with acromegaly. Growth Horm IGF Res 59:101389. https:\/\/doi.org\/10.1016\/j.ghir.2021.101389","journal-title":"Growth Horm IGF Res"},{"issue":"4","key":"965_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"965_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"key":"965_CR14","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD et al (2021) Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne) 12:627711. https:\/\/doi.org\/10.3389\/fendo.2021.627711","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"965_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107(2):297\u2013308. https:\/\/doi.org\/10.1210\/clinem\/dgab726","journal-title":"J Clin Endocrinol Metab"},{"key":"965_CR16","doi-asserted-by":"publisher","first-page":"648411","DOI":"10.3389\/fendo.2021.648411","volume":"12","author":"M Puig-Domingo","year":"2021","unstructured":"Puig-Domingo M, Bernab\u00e9u I, Pic\u00f3 A, Biagetti B, Gil J, Alvarez-Escol\u00e1 C et al (2021) Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne) 12:648411. https:\/\/doi.org\/10.3389\/fendo.2021.648411","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"965_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41687-023-00541-7","volume":"7","author":"S Martin","year":"2023","unstructured":"Martin S, Bender RH, Krasner A, Marmon T, Monahan M, Nelson L (2023) Development and evaluation of the acromegaly symptom diary. J Patient Rep Outcomes 7(1):15. https:\/\/doi.org\/10.1186\/s41687-023-00541-7","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"965_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4(5):353\u2013365","journal-title":"PharmacoEconomics"},{"key":"965_CR19","volume-title":"Pain: clinical manual for nursing practice","author":"M McCaffery","year":"1989","unstructured":"McCaffery M, Beebe A (1989) Pain: clinical manual for nursing practice. Mosby, St. Louis, MO"},{"key":"965_CR20","doi-asserted-by":"publisher","unstructured":"Katsarava Z, Buse DC, Leroux E, Lanteri-Minet M, Sakai F, Matharu MS et al (2024) Disability in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study. Cephalalgia 44(8):3331024241274343. https:\/\/doi.org\/10.1177\/03331024241274343","DOI":"10.1177\/03331024241274343"},{"issue":"1","key":"965_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/13696998.2023.2172282","volume":"26","author":"S Rojanasarot","year":"2023","unstructured":"Rojanasarot S, Bhattacharyya SK, Edwards N (2023) Productivity loss and productivity loss costs to united States employers due to priority conditions: a systematic review. J Med Econ 26(1):262\u2013270. https:\/\/doi.org\/10.1080\/13696998.2023.2172282","journal-title":"J Med Econ"},{"issue":"10","key":"965_CR22","doi-asserted-by":"publisher","first-page":"bvad104","DOI":"10.1210\/jendso\/bvad104","volume":"7","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Barkan A, Brue T, Duquesne E, Houchard A, Del Pilar Schneider M et al (2023) Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis. J Endocr Soc 7(10):bvad104. https:\/\/doi.org\/10.1210\/jendso\/bvad104","journal-title":"J Endocr Soc"},{"issue":"1","key":"965_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","volume":"20","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S et al (2020) Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord 20(1):117. https:\/\/doi.org\/10.1186\/s12902-020-00595-4","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"965_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/EJE-15-1042","volume":"174","author":"CJ Strasburger","year":"2016","unstructured":"Strasburger CJ, Karavitaki N, St\u00f6rmann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M et al (2016) Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol 174(3):355\u2013362. https:\/\/doi.org\/10.1530\/EJE-15-1042","journal-title":"Eur J Endocrinol"},{"key":"965_CR25","doi-asserted-by":"publisher","unstructured":"Siegel S, Kirstein CF, Schr\u00f6der B, Unger N, Kreitschmann-Andermahr I (2021) Illness-related burden, personal resources and need for support in patients with acromegaly: results of a focus group analysis. Growth Horm IGF Res. 60\u201361. https:\/\/doi.org\/10.1016\/j.ghir.2021.101422","DOI":"10.1016\/j.ghir.2021.101422"},{"issue":"3","key":"965_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1530\/EJE-21-0729","volume":"186","author":"S Arnard\u00f3ttir","year":"2022","unstructured":"Arnard\u00f3ttir S, J\u00e4r\u00e5s J, Burman P, Berinder K, Dahlqvist P, Erfurth EM et al (2022) Long-term outcomes of patients with acromegaly: a report from the Swedish pituitary register. Eur J Endocrinol 186(3):329\u2013339. https:\/\/doi.org\/10.1530\/EJE-21-0729","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"965_CR27","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00701-023-05772-7","volume":"165","author":"CM Falch","year":"2023","unstructured":"Falch CM, Dupont AK, Olarescu NC, Wiedmann M, Dahlberg D, Bollerslev J et al (2023) Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir (Wien) 165(10):3003\u20133010. https:\/\/doi.org\/10.1007\/s00701-023-05772-7","journal-title":"Acta Neurochir (Wien)"},{"key":"965_CR28","doi-asserted-by":"publisher","first-page":"610519","DOI":"10.3389\/fendo.2020.610519","volume":"11","author":"X Guo","year":"2020","unstructured":"Guo X, Wang K, Yu S, Gao L, Wang Z, Zhu H et al (2020) Patient characteristics, diagnostic delays, treatment patterns, treatment outcomes, comorbidities, and treatment costs of acromegaly in china: a nationwide study. Front Endocrinol (Lausanne) 11:610519. https:\/\/doi.org\/10.3389\/fendo.2020.610519","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"965_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/MPA.0b013e318279d552","volume":"42","author":"AE Boyd","year":"2013","unstructured":"Boyd AE, DeFord LL, Mares JE, Garris CLC, Dagohoy JL CG et al (2013) Improving the success rate of gluteal intramuscular injections. Pancreas 42(5):878\u2013882. https:\/\/doi.org\/10.1097\/MPA.0b013e318279d552","journal-title":"Pancreas"},{"issue":"9","key":"965_CR30","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","volume":"107","author":"L Maione","year":"2022","unstructured":"Maione L, Albrici C, Grunenwald S, Mouly C, Cimino V, Lecoq AL et al (2022) IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands. J Clin Endocrinol Metab 107(9):e3644\u2013e3653. https:\/\/doi.org\/10.1210\/clinem\/dgac385","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"965_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K et al (2016) Effect of Pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53(1):210\u2013219. https:\/\/doi.org\/10.1007\/s12020-016-0895-8","journal-title":"Endocrine"},{"key":"965_CR32","unstructured":"Mycapssa delayed-release (2024) capsules, for oral use [package insert]. Ciesi Farmaceutici S.p.A."},{"key":"965_CR33","unstructured":"Somavert (pegvisomant) for injection, for subcutaneous use [package insert]. Pfizer Inc.; (2023)"},{"issue":"4","key":"965_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/03007995.2024.2314244","volume":"40","author":"J Sisco","year":"2024","unstructured":"Sisco J, Furumalm M, Yssing C, Okkels A, Zavisic S (2024) Preferences for different treatment options among people living with acromegaly in the US. Curr Med Res Opin 40(4):657\u2013664. https:\/\/doi.org\/10.1080\/03007995.2024.2314244","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"965_CR35","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.3171\/2023.8.FOCUS23467","volume":"55","author":"M Sabahi","year":"2023","unstructured":"Sabahi M, Maroufi SF, Wierzbicka A, Maniakhina L, Adada B, Borghei-Razavi H (2023) Healthcare disparities in pituitary surgery: a systematic review. Neurosurg Focus 55(5):E15. https:\/\/doi.org\/10.3171\/2023.8.FOCUS23467","journal-title":"Neurosurg Focus"},{"issue":"12","key":"965_CR36","doi-asserted-by":"publisher","first-page":"e220385","DOI":"10.1530\/EC-22-0385","volume":"11","author":"SM Webb","year":"2022","unstructured":"Webb SM, Kristensen J, Nordenstr\u00f6m A, Vitali D, Amodru V, Wiehe LK et al (2022) Patient journey experiences May contribute to improve healthcare for patients with rare endocrine diseases. Endocr Connect 11(12):e220385. https:\/\/doi.org\/10.1530\/EC-22-0385","journal-title":"Endocr Connect"},{"key":"965_CR37","doi-asserted-by":"publisher","unstructured":"Quock TP, Chang E, Das AK, Speller A, Tarbox MH, Rossi ML et al (2025) Healthcare utilization and costs among patients with acromegaly in the United States. J Comp Eff Res 2025:e250069. https:\/\/doi.org\/10.57264\/cer-2025-0069","DOI":"10.57264\/cer-2025-0069"},{"issue":"1","key":"965_CR38","doi-asserted-by":"publisher","first-page":"bvab176","DOI":"10.1210\/jendso\/bvab176","volume":"6","author":"AG Ioachimescu","year":"2021","unstructured":"Ioachimescu AG, Goswami N, Handa T, Pappy A, Veledar E, Oyesiku NM (2021) Racial disparities in acromegaly and cushing\u2019s disease: a referral center study in 241 patients. J Endocr Soc 6(1):bvab176. https:\/\/doi.org\/10.1210\/jendso\/bvab176","journal-title":"J Endocr Soc"},{"key":"965_CR39","unstructured":"US Department of Health and Human Services (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf. Last updated Published December Accessed May 16"},{"key":"965_CR40","unstructured":"Geer EB, Clemmons D, Sisco J, Koobatian M, Okeyo J, Quock T et al Impact of symptom exacerbations in patients with medically treated acromegaly. Presented at American Association of Clinical Endocrinology Annual Meeting; May 15\u201317, 2025; Orlando, FL"},{"issue":"4","key":"965_CR41","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1210\/jc.2004-2009","volume":"90","author":"JJ Puder","year":"2005","unstructured":"Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90(4):1972\u20131978. https:\/\/doi.org\/10.1210\/jc.2004-2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"965_CR42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ et al (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859\u2013868. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02825.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"965_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11102-015-0693-y","volume":"19","author":"PJ Caron","year":"2016","unstructured":"Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM et al (2016) Effects of Lanreotide autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19(2):149\u2013157. https:\/\/doi.org\/10.1007\/s11102-015-0693-y","journal-title":"Pituitary"},{"issue":"3","key":"965_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF03346453","volume":"32","author":"G Lombardi","year":"2009","unstructured":"Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arrnaldi G, Arosio M et al (2009) Efficacy of the new long-acting formulation of Lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 32(3):202\u2013209. https:\/\/doi.org\/10.1007\/BF03346453","journal-title":"J Endocrinol Invest"},{"issue":"Suppl 1","key":"965_CR45","doi-asserted-by":"publisher","first-page":"A723","DOI":"10.1210\/jendso\/bvad114.1355","volume":"7","author":"EB Geer","year":"2023","unstructured":"Geer EB, Huang W, Gordon MB, Yuen KCJ, Lubitz SE, Salvatori R et al (2023) Matched physician- and patient-reported responses of acromegaly symptom control: comparisons from the MACRO registry [abstract SAT622]. J Endocr Soc 7(Suppl 1):A723. https:\/\/doi.org\/10.1210\/jendso\/bvad114.1355","journal-title":"J Endocr Soc"},{"key":"965_CR46","doi-asserted-by":"crossref","unstructured":"Luo R, Burke G, Mui C, Shakib S, Ferrara-Cook C, Krasner A et al (2021) Pharmacokinetics and safety of an improved oral formulation of paltusotine, a selective, nonpeptide somatostatin receptor 2 (SST2) agonist for the treatment of acromegaly. Presented at Endocrine Society\u2019s Annual Meeting ENDO. ; March 20\u201323, 2021; virtual","DOI":"10.1210\/jendso\/bvab048.1068"},{"issue":"2","key":"965_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","volume":"25","author":"A Madan","year":"2022","unstructured":"Madan A, Markison S, Betz SF, Krasner A, Luo R, Jochelson T et al (2022) Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary 25(2):328\u2013339. https:\/\/doi.org\/10.1007\/s11102-021-01201-z","journal-title":"Pituitary"},{"issue":"1","key":"965_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao J, Wang S, Markison S, Kim SH, Han S, Chen M et al (2023) Discovery of Paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist. ACS Med Chem Lett 14(1):66\u201374. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00431","journal-title":"ACS Med Chem Lett"},{"key":"965_CR49","unstructured":"Crinetics Pharmceuticals Inc (2024) Crinetics announces FDA acceptance of new drug application for Paltusotine for adult patients with acromegaly [Press Release]. December 9"},{"issue":"1","key":"965_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1210\/clinem\/dgae385","volume":"110","author":"MR Gadelha","year":"2024","unstructured":"Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA et al (2024) Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral Paltusotine. J Clin Endocrinol Metab 110(1):228\u2013237. https:\/\/doi.org\/10.1210\/clinem\/dgae385","journal-title":"J Clin Endocrinol Metab"},{"key":"965_CR51","doi-asserted-by":"crossref","unstructured":"Biller BMK, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B et al (2024) Efficacy and safety of once-daily oral Paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled PATHFNDR-2 study. Presented ENDO. 1\u20134, 2024; Boston, MA.","DOI":"10.1210\/jendso\/bvae163.1201"},{"issue":"6","key":"965_CR52","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","volume":"110","author":"D Ferone","year":"2025","unstructured":"Ferone D, Freda P, Katznelson L, Gatto F, Kadio\u011flu P, Maffei P et al (2025) Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab 110(6):1729\u20131739. https:\/\/doi.org\/10.1210\/clinem\/dgae707","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"965_CR53","doi-asserted-by":"publisher","first-page":"105030","DOI":"10.1016\/j.jbc.2023.105030","volume":"299","author":"R Basu","year":"2023","unstructured":"Basu R, Brody R, Sandbhor U, Kulkarni P, Davis E, Swegan D et al (2023) Structure and function of a dual antagonist of the human growth hormone and prolactin receptors with site-specific PEG conjugates. J Biol Chem 299(8):105030. https:\/\/doi.org\/10.1016\/j.jbc.2023.105030","journal-title":"J Biol Chem"},{"key":"965_CR54","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.jbc.2021.100588","volume":"296","author":"R Basu","year":"2021","unstructured":"Basu R, Nahar K, Kulkarni P, Kerekes O, Sattler M, Hall Z et al (2021) A novel peptide antagonist of the human growth hormone receptor. J Biol Chem 296:100588. https:\/\/doi.org\/10.1016\/j.jbc.2021.100588","journal-title":"J Biol Chem"},{"key":"965_CR55","doi-asserted-by":"crossref","unstructured":"Allas S, Weiler T, Ravel G, Farrell C, Fillon S, Rouis TO et al (2024) A phase 1 clinical study to evaluate the safety, tolerability, pharmcokinetics and pharmacodynamics of AZP-3813, a novel, small peptide growth hormone receptor antagonist in healthy subjects. Presented ENDO. 1\u20134, 2024; Boston, MA.","DOI":"10.1530\/endoabs.99.RC5.4"},{"issue":"Suppl 1","key":"965_CR56","doi-asserted-by":"publisher","first-page":"A511","DOI":"10.1210\/jendso\/bvac150","volume":"6","author":"M Culler","year":"2022","unstructured":"Culler M, Milano S, Kurasaki H, Tomiyama T, Reid P, van der Lely A et al (2022) Sustained suppression of IGF1 with AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor and a potential new treatment for acromegaly [abstract]. J Endocr Soc 6(Suppl 1):A511. https:\/\/doi.org\/10.1210\/jendso\/bvac150","journal-title":"J Endocr Soc"},{"key":"965_CR57","first-page":"P148","volume":"81","author":"S Milano","year":"2022","unstructured":"Milano S, Kurasaki H, Tomiyama T, Reid P, Van der Lely A, Culler MD (2022) AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor as a potential new treatment for acromegaly [abstract P148]. Endocr Abst 81:P148","journal-title":"Endocr Abst"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00965-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:15:52Z","timestamp":1764944152000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00965-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00965-3","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Although regulatory criteria for exemption from institutional review board review were met since all collected data were anonymized, review board approval was still obtained for the daily symptom survey and the exit survey of patient experiences. Patients provided consent for analysis of their survey results and received honoraria to compensate for their time for survey completion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MK, JCO, AK, and TPQ are employees of Crinetics Pharmaceuticals, Inc. JS reports serving as a consultant for Alexion, Camurus, Chiesi, Debiopharm, and Recordati; and serving on advisory boards for Crinetics and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}